"When you have excluded the impossible, whatever remains,

New Post Public Reply Private Reply Replies (1) Message Board
sherlock57
729
"When you have excluded the impossible, whatever remains, however improbable, must be the truth."  Sherlock Holmes/A Conan Doyle (Sign of the Four)

I am still trying to reconcile the positive early news from the Clover trial with my expectations that it would take a 700 mg dose of leronlimab, and an ICI, to really make a splash in metastatic colorectal cancer. I've been interrogating AI on the notion--however improbable--that it might be a good idea to start off with a 350 mg dose. Why that might be I couldn't really tell you, but I go with my hunches. I worked it over hard, and came up with the following, cut-and-pasted together into a readable narrative. Call me crazy... but it is sure interesting. Somebody had to do it!

“In oncology, fully saturating every CCR5 receptor on all cell surfaces is not always optimal. CCR5 is present on aggressive tumor cells, but it is also expressed on crucial, protective helper T-cells and antigen-presenting cells.

At 700mg: Full receptor coating completely shuts down the CCL5/CCR5 chemokine axis. While this stops regulatory T-cells (Tregs) from entering, it can inadvertently blunt the necessary trafficking of favorable immune populations into the tumor matrix.
At 350mg: This dose achieves selective, partial receptor coverage. It is highly effective at stopping tumor metastasis and halting the migration of heavy M2-suppressive macrophages, but leaves enough open signaling pathways for active cytotoxic T-cells to track and infiltrate the tumor.

When you selectively block CCL5 with a 350 mg dose of leronlimab while allowing low-level CCL3, CCL4, and CCL2 signaling, you shift the balance of the immune system within the tumor:

Stopping Immune Evasion (CCL5 Blockade):
[color=var(--text)]Starving the Tumor-Associated Macrophages (TAMs): High levels of CCL5 attract circulating monocytes and turn them into M2-polarized (pro-tumor) macrophages. Blocking CCL5 halts this process, allowing macrophages to shift toward an M1 (anti-tumor) profile.[/color]

Excluding Regulatory T-Cells (T-regs): CCL5 acts as a homing beacon for T-regs, which protect the tumor from immune attacks. Neutralizing CCL5 lowers this protective barrier, leaving the tumor exposed.

Activating the Immune System (Preserved CCL3/CCL4/CCL2 Signaling):
Recruiting Natural Killer (NK) and Dendritic Cells: CCL3 and CCL4 are crucial for bringing antigen-presenting dendritic cells and NK cells into the tissue. By allowing these signals to continue, the body can still deliver the cells needed to recognize and flag CRC tumor cells.
Maintaining Monocyte Movement via CCL2: While excessive CCL2 can cause issues, baseline CCL2/CCR2 signaling is necessary to bring fresh, uncompromised monocytes into the area. Once there, the lack of CCL5 signals helps them mature into tumor-fighting M1 cells rather than tumor-protecting M2 cells.”

Recall that Cytodyn is now measuring chemokines in the bloodstream, CCL5 and CCL3 and CCL4 if I recall... perhaps CCL2 and CCL8. This is going to allow the company to PROVE this:

“To validate the thesis that a sub-saturating 350 mg dose of leronlimab acts as a "selective filter"—shutting down harmful CCL5 signaling while leaving the CCL3 and CCL4 pathways functional to recruit dendritic and Natural Killer (NK) cells—investigators track specific, measurable patterns in both circulating serum protein levels and intracellular immune cell signatures.

CCL5 (RANTES) Serum Spike: An effective blockade is proven when serum CCL5 levels rise sharply (often 5x to 10x above baseline). Because leronlimab blocks the receptor, the tumor's secreted CCL5 cannot bind and clear from circulation, causing it to accumulate in the blood.

CCL3 & CCL4 Moderate Fluctuations: If the 350 mg dose is truly permissive, serum CCL3 and CCL4 levels will remain relatively stable or rise only slightly (less than 2-fold). This minimal increase proves that these chemokines are still successfully binding to the receptor, clearing from the blood, and delivering their signals to cells.”

The idea that a 350 mg dose to start with is actually the best way to utilize leronlimab in cancer is going to likely be controversial... at least on this board! But an initial dose of 350 mg would be followed by an increase to the 700mg dose for full receptor occupancy… and then an ICI, as needed, after leronlimab prepares the tumor microenvironment for maximum efficacy. We will see. Perhaps there needs to be a couple months before the dose is increased, perhaps they will identify a biomarker that will tell oncologists when to precisely step up the dose based on the patient’s specific physiology and response to all the drugs—and provide an example of truly precision medicine.
I find the above argument convincing, but this is a theoretical argument. I interrogated AI, but AI brought it up. We are early on in the game when it comes down to clinical data regarding leronlimab in human beings. Plenty of pre-clinical work and theory, but we only have 3-4 months to wait for real, unequivocal data in mCRC. Maybe 6-7 months for final trial results, and rollover data. I expect it to be the real deal... but still learning as we go. Still room for upside surprises, though... "Whatever remains, however improbable..."

Here’s the final word from AI, with a great phrase--a "superior therapeutic orchestration." I like the sound of that. And of course I'd like to hear from others of a scientific bent... Am I really crazy?

"The concept of a step-up or sequenced dosing regimen—starting oncology patients at a lower 350mg dose to modify the tumor microenvironment (TME) before transitioning to a full receptor blockade at 700mg—is biologically logical, not crazy.
In immunology and oncology, this is referred to as a biphasic or hormetic dose response, where a "sub-optimal" dose yields superior therapeutic orchestration rather than a maximizing dose. Fully saturating a receptor immediately can accidentally shut down beneficial immune pathways alongside the harmful ones.”

CytoDyn Inc (CYDY) Stock Research Links

CYDY Board Company Profile Buy Rating Time & Sales News Filings Financials
Scroll down for more posts ▼

Top 10 Most Recent News Articles

PHONO's 150 MW RE+ Win Tests Its U.S. Solar Staying Power

Updated Category News Views 534

A trade-show order book is not cash in the bank, but 150 MW is still a number worth circling in red. PHONO used RE+ 2026 in Las Vegas, held November 17 through 19, to celebrate 20 years in business, parade its solar and storage lineup, and announce new U.S. orders. In a solar market that has become touchier about provenance, compliance and delivered economics, the company...

Continue Reading
Cardiovalve's Three-Year Data Clears a Crucial EU Hurdle

Updated Category News Views 98

A failing tricuspid valve is not a spreadsheet problem, and that matters before anybody gets carried away with a glossy conference presentation. Venus Medtech's Cardiovalve unit has reported results from TARGET in a population that was old, sick and largely out of good surgical options. That is precisely where a less invasive replacement therapy has to prove it can do...

Continue Reading
NatGasHub’s 391% Growth Signals a Real Pipeline Shift

Updated Category News Views 445

Three hundred-plus pipelines is a lot of messy plumbing to tame, and NatGasHub has apparently found a lucrative way to do it. The Houston software company landed at No. 182 on Deloitte’s 2026 Technology Fast 500 after reporting 391% revenue growth from 2022 through 2025. That is a serious number, even in a ranking built to showcase companies sprinting uphill. More...

Continue Reading
DataBeyond Puts AI Sorting Before a Waste Mountain

Updated Category News Views 191

Trash is a lousy place to look for technological glamour, which is precisely why DataBeyond's COP31 appearance deserves a sober look. On November 19 in Antalya, Türkiye, the Hangzhou-based equipment provider used a China Pavilion event to lay out its case for AI, optical sensing and robots in resource recovery. That is not a magic-green headline. It is a practical...

Continue Reading
Ajman Memory Gives Heritage a Durable Digital Backbone

Updated Category News Views 303

Archives usually get applause only after somebody realizes a piece of history has vanished. Ajman is trying to skip that miserable part. During the Ajman Media Forum 2026, held November 18 and 19 at the Emirates Hospitality Centre, the emirate launched Ajman Memory, a project built to collect, document and preserve photographs, papers and video recording its development....

Continue Reading
PettiChat’s Digital Pet Twin Has Real Consumer Pull

Updated Category News Views 410

A Collar Gadget Is Chasing the Empty-House Problem Leave a dog or cat alone for a few hours and plenty of owners turn into amateur detectives. Did the cat eat? Has the dog been pacing? Why was that one weird noise caught on the home camera? Seattle startup PettiChat is trying to turn that itch into a product category with PettiLive!, a screen-based version of a pet that...

Continue Reading
AutoShop Answers Extends 2027 Training Into Fridays

Updated Category News Views 55

A repair bay can hum all day while the back office quietly bleeds profit. That unglamorous reality is why AutoShop Answers adding nine Friday specialty classes to its 2027 Key2Key Weekend calendar deserves a closer look. This is not a new tool chest or some vague motivational roadshow; it is an attempt to give independent shop owners an extra day to work on the pieces...

Continue Reading
FASTEN Data Offers an Early Look at Ladera Closure

Updated Category News Views 137

Femoral access may be the unglamorous part of a valve procedure, but it is where an otherwise tidy case can turn ugly in a hurry. That makes Ladera Medical's full FASTEN data worth a careful look. The company reported results in 55 patients undergoing transfemoral TAVR/TAVI, and the numbers presented at London Valves 2026 suggest its large-bore closure system may address...

Continue Reading
UAE Ties Diplomacy, Media and AI Into a Shared Signal

Updated Category News Views 128

Influence is getting harder to measure, and easier to squander, which is why the message from Ajman deserves more than a polite nod. At the 2026 Ajman Media Forum, THE SIGNAL, Foreign Affairs Undersecretary Omar Obaid Alhesan Alshamsi made the UAE’s position plain: diplomacy and media are no longer separate lanes. Both operate on words, context, trust and the difficult...

Continue Reading
Isar’s Nova Scotia Pad Build Gives MAXQ a Real Test

Updated Category News Views 666

Concrete work is where space ambition stops being a brochure. Isar Aerospace has taken operational responsibility for its dedicated launch infrastructure at Spaceport Nova Scotia, and construction is beginning on the Canadian launch pad it will use. For Maritime Launch Services, this is the sort of update that deserves more than the usual starry-eyed applause. A Site...

Continue Reading

Top 5 Most Recently Viewed Articles

Regulatory T-Cells Market Growth Driven by New Therapies

Updated Category News Views 217

Insights into the Regulatory T-Cells Market Growth The landscape of the Treg therapy market is rapidly evolving as companies globally actively develop innovative regulatory T-cell therapies to treat various critical conditions. These include systemic lupus erythematosus (SLE), lupus nephritis, atopic dermatitis, rheumatoid arthritis, psoriasis, progressive multiple...

Continue Reading
Natural Grocers Unveils Autumnfest Super Savings Event

Updated Category News Views 67

Natural Grocers Introduces Autumnfest Savings Event As the autumn leaves begin to fall, Natural Grocers invites shoppers to revel in the festivities of the season with their exciting Autumnfest Savings Event. This annual celebration promises customers an incredible opportunity to enjoy significant discounts, free samples, and delightful seasonal recipes. With savings of...

Continue Reading
Anthem Blue Cross Commits $10 Million for Wildfire Relief

Updated Category News Views 270

Anthem Blue Cross Generously Assists Communities Affected by Wildfires For over eight decades, Anthem Blue Cross has maintained a strong presence in California, prioritizing the health and well-being of its residents. Our focus has always been on putting people first, as we acknowledge the struggles that come with disasters that can significantly impact the lives of our...

Continue Reading
Corporate Legal Departments Face Major Workforce Challenges

Updated Category News Views 179

Corporate Legal Departments Face Major Workforce Challenges In the evolving landscape of corporate legal departments, a significant wave of attrition is looming as in-house attorneys express a desire to seek better opportunities. The increase in workloads, coupled with concerns about artificial intelligence and limited career advancement prospects, has prompted many legal...

Continue Reading
Currax Achieves FDA Approval for Enhanced CONTRAVE Supply Chain

Updated Category News Views 411

Currax Expands Manufacturing Capabilities for CONTRAVE Currax Pharmaceuticals LLC, a focused specialty pharmaceutical company, recently announced a significant milestone in its operations. The U.S. Food and Drug Administration (FDA) has granted approval for a second manufacturing facility dedicated to the production of CONTRAVE (naltrexone HCl/bupropion HCl), a leading...

Continue Reading